AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39455971 — intervention group
Group type: EXPERIMENTAL
Intervention: Music group (listened to a 29-minute and 32-second song three days before menstruation and on the first day of menstruation in the third month)
Number of subjects: 96
Study 39455971 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing group (created art for the same duration as the music group)
Number of subjects: 96
Study 39455971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 39455976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women in third trimester
Number of subjects: 198
Study 39455976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 198
Study 39455976 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 198
Study 39455996 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tufted toothbrush (ST-TB)
Number of subjects: 36
Study 39455996 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic toothbrush (O-TB)
Number of subjects: 36
Study 39455996 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush (C-TB)
Number of subjects: 36
Study 39456048 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized high PEEP strategy with recruitment maneuvers (RMs)
Number of subjects: 1806
Study 39456048 — intervention group
Group type: COMPARATOR
Intervention: Standard low PEEP of 5 cm H2O without recruitment maneuvers (RMs)
Number of subjects: 1806
Study 39456051 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Collaborative Assessment (MCA)
Number of subjects: 0
Study 39456051 — intervention group
Group type: COMPARATOR
Intervention: Standard Assessment (Control)
Number of subjects: 0
Study 39456079 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (healthcare facility-based passive case detection with smear microscopy testing)
Number of subjects: 48
Study 39456079 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice (active case finding and Xpert MTB/RIF Ultra PCR testing followed by household contact investigations)
Number of subjects: 48
Study 39456079 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel intervention (active case finding, Xpert MTB/RIF Ultra PCR testing, sputum culture, and M. tuberculosis whole genome sequencing)
Number of subjects: 48
Study 39456081 — intervention group
Group type: EXPERIMENTAL
Intervention: GAIN Lite added to enhanced usual care (EUC)
Number of subjects: 132
Study 39456081 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) only
Number of subjects: 132
Study 39456544 — intervention group
Group type: EXPERIMENTAL
Intervention: Empiric intravenous broad-spectrum antibiotics (IVBSA) for at least 48 h with PCT monitoring
Number of subjects: 89
Study 39456544 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT drop (defined as a reduction of 30% from baseline or a PCT level < 0.25 ng/mL)
Number of subjects: 89
Study 39457149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 0
Study 39457194 — intervention group
Group type: EXPERIMENTAL
Intervention: Music enrichment program
Number of subjects: 16
Study 39457194 — intervention group
Group type: COMPARATOR
Intervention: Play date control
Number of subjects: 16
Study 39457678 — intervention group
Group type: EXPERIMENTAL
Intervention: NP001 (1 mg/kg or 2 mg/kg)
Number of subjects: 268
Study 39457678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 39458142 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation Genetic Testing for Aneuploidy (PGT-A)
Number of subjects: 0
Study 39458142 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard IVF treatment)
Number of subjects: 0
Study 39458156 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality treatment
Number of subjects: 0
Study 39458224 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39458438 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg/kg) administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Number of subjects: 41
Study 39458438 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Number of subjects: 41
Study 39460685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) as adjunctive therapy
Number of subjects: 239
Study 39460694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan
Number of subjects: 340
Study 39460694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 39460719 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ocrelizumab (up to 1200 mg)
Number of subjects: 135
Study 39460719 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ocrelizumab (920 mg)
Number of subjects: 135
Study 39460719 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ocrelizumab (600 mg)
Number of subjects: 135
Study 39460896 — intervention group
Group type: EXPERIMENTAL
Intervention: UWF-FFA
Number of subjects: 60
Study 39460896 — intervention group
Group type: EXPERIMENTAL
Intervention: SS-OCTA
Number of subjects: 60
Study 39460896 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP
Number of subjects: 60
Study 39460896 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IRMA
Number of subjects: 60
Study 39460896 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between IRMA and microaneurysms
Number of subjects: 60
Study 39461270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV) 6 mg/kg adjusted ideal body weight every 3 weeks
Number of subjects: 682
Study 39461299 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraglutide (once-weekly subcutaneous injections)
Number of subjects: 9
Study 39461302 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV vaccine
Number of subjects: 18348
Study 39461302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18348
Study 39461733 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 900 IU/kg (300 IU/kg/day)
Number of subjects: 95
Study 39461733 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 1800 IU/kg (600 IU/kg/day)
Number of subjects: 95
Study 39461733 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 3600 IU/kg (600 IU/kg/day on presentation and then 1 month later)
Number of subjects: 95
Study 39461733 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study 39461739 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-capsule BQT containing bismuth, metronidazole, tetracycline, and a proton pump inhibitor (PPI)
Number of subjects: 15682
Study 39461739 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day Single-capsule BQT (ScBQT)
Number of subjects: 15682
Study 39461739 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day BQT using tetracycline plus metronidazole or amoxicillin plus either clarithromycin or metronidazole
Number of subjects: 15682
Study 39461739 — intervention group
Group type: EXPERIMENTAL
Intervention: ScBQT scheme
Number of subjects: 15682
Study 39461792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g by slow intravenous injection within 15 min of umbilical cord clamping)
Number of subjects: 15068
Study 39461792 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo by slow intravenous injection within 15 min of umbilical cord clamping)
Number of subjects: 15068
Study 39461860 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (three times per week using a diode laser device, starting on the first day of conditioning and continuing through day 3 post-transplant)
Number of subjects: 30
Study 39461860 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 30
Study 39461860 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study 39461861 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane delivered via the Sedaconda ACD-S
Number of subjects: 235
Study 39461861 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propofol
Number of subjects: 235
Study 39461864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 200 mg QD for 24 weeks
Number of subjects: 25
Study 39461864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg QD for 24 weeks
Number of subjects: 25
Study 39461864 — intervention group
Group type: COMPARATOR
Intervention: External published data from an edaravone study (MCI186-19)
Number of subjects: 25
Study 39461864 — intervention group
Group type: COMPARATOR
Intervention: Registry data from a multicentre ALS cohort study
Number of subjects: 25
Study 39461869 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperpolarised [1-
Number of subjects: 30
Study 39461869 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 30
Study 39461878 — intervention group
Group type: EXPERIMENTAL
Intervention: AdAPT-001 plus a checkpoint inhibitor (CI)
Number of subjects: 0
Study 39461878 — intervention group
Group type: COMPARATOR
Intervention: Checkpoint inhibitor (CI)
Number of subjects: 0
Study 39461901 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of low-load blood flow restricted resistance training (BFR-RT) 3x/week
Number of subjects: 86
Study 39461901 — intervention group
Group type: COMPARATOR
Intervention: Preoperative usual care (CON) involving no exercise
Number of subjects: 86
Study 39461915 — intervention group
Group type: EXPERIMENTAL
Intervention: IV omadacycline or linezolid
Number of subjects: 1380
Study 39461915 — intervention group
Group type: COMPARATOR
Intervention: Oral omadacycline or linezolid
Number of subjects: 1380
Study 39461964 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnidirectional subthalamic deep brain stimulation (OS)
Number of subjects: 19
Study 39461964 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional subthalamic deep brain stimulation (DS)
Number of subjects: 19
Study 39461973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-network gene community detection (MNGCD) approach applied to whole blood samples
Number of subjects: 0
Study 39461973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-network gene community detection (MNGCD) approach
Number of subjects: 0
Study 39461973 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial infections (Moraxella catarrhalis and Haemophilus influenzae) during acute exacerbations
Number of subjects: 0
Study 39461975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 55
Study 39461975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 39462030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate at 15 °C
Number of subjects: 18
Study 39462030 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate at 37 °C
Number of subjects: 18
Study 39462122 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with major alleles for SNP rs864537A > G in CD247 (AA genotype) born March-August
Number of subjects: 6523
Study 39462122 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with febrile infections between ages 3-6 months
Number of subjects: 6523
Study 39462179 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic strategies targeting metabolic vulnerabilities in cancer cells
Number of subjects: 0
Study 39462240 — intervention group
Group type: EXPERIMENTAL
Intervention: Microaxial flow pump (MAFP)
Number of subjects: 324
Study 39462240 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 324
Study 39462276 — intervention group
Group type: EXPERIMENTAL
Intervention: microaxial flow pump (mAFP)
Number of subjects: 355
Study 39462276 — intervention group
Group type: COMPARATOR
Intervention: standard care alone
Number of subjects: 355
Study 39462308 — intervention group
Group type: EXPERIMENTAL
Intervention: Atacicept
Number of subjects: 0
Study 39462310 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Endothelin Receptor Antagonist SC0062
Number of subjects: 0
Study 39462310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39462335 — intervention group
Group type: EXPERIMENTAL
Intervention: AgeMatchPLUS intervention (virtual partner-based peer support exercise intervention)
Number of subjects: 18
Study 39462335 — intervention group
Group type: EXPERIMENTAL
Intervention: AgeMatchPLUS intervention
Number of subjects: 18
Study 39462335 — intervention group
Group type: COMPARATOR
Intervention: AgeMatch (control group)
Number of subjects: 18
Study 39462341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored arm (TA)
Number of subjects: 42
Study 39462341 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (SA)
Number of subjects: 42
Study 39462354 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching (5 monthly calls from physiotherapist)
Number of subjects: 99
Study 39462354 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program alone (control group)
Number of subjects: 99
Study 39462425 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-confidence
Number of subjects: 395
Study 39462425 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function
Number of subjects: 395
Study 39462425 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 395
Study 39462425 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 395
Study 39462433 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS at 80% intensity
Number of subjects: 20
Study 39462433 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study 39462517 — intervention group
Group type: EXPERIMENTAL
Intervention: MBA-P01 (20 U, five treatments over 16 months)
Number of subjects: 0
Study 39462835 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + short course of carbon ion radiotherapy (CIRT) followed by surgery and adjuvant chemotherapy
Number of subjects: 0
Study 39463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 or 20 mg/day)
Number of subjects: 0
Study 39463173 — intervention group
Group type: COMPARATOR
Intervention: Desvenlafaxine (50 mg/day)
Number of subjects: 0
Study 39463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0
Study 39463187 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 137
Study 39463187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 39463194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction (CLC) with AH Plus sealer (G1)
Number of subjects: 24
Study 39463194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction (CLC) with Endosequence (ES) after standard canal dryness (SD) (G2)
Number of subjects: 24
Study 39463194 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching single-cone (SC) with ES after standard canal dryness (SD) (G3)
Number of subjects: 24
Study 39463194 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching single-cone (SC) with ES after partial canal dryness (PD) (G4)
Number of subjects: 24
Study 39463194 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cone obturation technique with HCSBS (ES or CeraSeal) after different dryness protocols (2nd phase)
Number of subjects: 24
Study 39463194 — intervention group
Group type: COMPARATOR
Intervention: Standard dryness protocol
Number of subjects: 24
Study 39463194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional root canal moisture
Number of subjects: 24
Study 39463195 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 49284
Study 39463195 — intervention group
Group type: COMPARATOR
Intervention: Patients with cardiac rupture (CR)
Number of subjects: 49284
Study 39463395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual microcirculatory assessment on admission
Number of subjects: 44
Study 39463748 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg twice daily for 2 years) plus endocrine therapy (ET)
Number of subjects: 501
Study 39463748 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 501
Study 39464181 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation (150 mGy 2x/week for 5 consecutive weeks)
Number of subjects: 15
Study 39464248 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative multidimensional approach for depression (CMAD)
Number of subjects: 394
Study 39464248 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 394
Study 39464260 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-recommended hyperkalaemia management including dietary potassium management
Number of subjects: 1330
Study 39464260 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioners' management decisions
Number of subjects: 1330
Study 39464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior (HB) intervention
Number of subjects: 0
Study 39464680 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Paleolithic elimination diet
Number of subjects: 0
Study 39464680 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (SOC)
Number of subjects: 0
Study 39464932 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 185
Study 39465217 — intervention group
Group type: EXPERIMENTAL
Intervention: Pritumumab (16.2 mg/kg weekly)
Number of subjects: 15
Study 39465257 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab (200 mg, day 1), anlotinib (10 mg, QD, PO, days 1-14), and platinum-based chemotherapy for 3 cycles, followed by adjuvant sintilimab (200 mg every 3 weeks).
Number of subjects: 45
Study 39465257 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment phase.
Number of subjects: 45
Study 39465257 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol set (PP set).
Number of subjects: 45
Study 39465257 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival.
Number of subjects: 45
Study 39465324 — intervention group
Group type: EXPERIMENTAL
Intervention: PG2 500 mg
Number of subjects: 66
Study 39465324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 39465350 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered-sunlight phototherapy (FSPT)
Number of subjects: 192
Study 39465350 — intervention group
Group type: COMPARATOR
Intervention: Intensive electric phototherapy (IEPT)
Number of subjects: 192
Study 39465397 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 73
Study 39465397 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous improvement
Number of subjects: 73
Study 39465397 — intervention group
Group type: COMPARATOR
Intervention: Minimal hepatic encephalopathy (MHE)
Number of subjects: 73
Study 39465397 — intervention group
Group type: COMPARATOR
Intervention: Presence of MHE
Number of subjects: 73
Study 39465531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC every 4 weeks
Number of subjects: 514
Study 39465531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 40 mg SC every 4 weeks (for bodyweight <40 kg)
Number of subjects: 514
Study 39465531 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 514
Study 39465752 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic oral appliance therapy (BOAT) device
Number of subjects: 17
Study 39465804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TGA
Number of subjects: 44
Study 39465804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a single TGA event
Number of subjects: 44
Study 39465804 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study 39465869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB) in Group 1 (VCI diameter < 1.5 cm, VCI-CI > 50%)
Number of subjects: 2
Study 39465869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB) in Group 2 (VCI diameter > 1.5 cm, VCI-CI < 50%)
Number of subjects: 2
Study 39465869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB)
Number of subjects: 2
Study 39465869 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB) in Group 1
Number of subjects: 2
Study 39465875 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 27q (27 gauge Quincke needle)
Number of subjects: 146
Study 39465875 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 146
Study 39465888 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (rhLF) at two doses
Number of subjects: 0
Study 39465888 — intervention group
Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 0
Study 39466126 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 100
Study 39466126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 39466174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 67
Study 39466174 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene control
Number of subjects: 67
Study 39466174 — intervention group
Group type: COMPARATOR
Intervention: Both CBT-I and Sleep hygiene control
Number of subjects: 67
Study 39466211 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 1105
Study 39466211 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1105
Study 39466215 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 1059
Study 39466215 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL Precision system
Number of subjects: 1059
Study 39466236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menaquinone 7), 180 μg, daily for 8 weeks
Number of subjects: 199
Study 39466236 — intervention group
Group type: COMPARATOR
Intervention: Placebo, daily for 8 weeks
Number of subjects: 199
Study 39466243 — intervention group
Group type: EXPERIMENTAL
Intervention: CP@clinic (intervention)
Number of subjects: 3695